Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H16ClN3O3S |
Molecular Weight | 365.835 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(Cl)C=C3)S(N)(=O)=O
InChI
InChIKey=NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. Indapamide is used for the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Antihypertensive action of indapamide. Comparative studies in several experimental models. | 1975 Oct |
|
Progress in reducing the burden of stroke. | 2001 Dec |
|
Effects of combination of low doses of angiotensin-converting enzyme inhibitor and diuretics on renal function in spontaneously hypertensive rats: comparison between acute and chronic treatment. | 2001 Jun |
|
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs]. | 2001 Sep |
|
Indapamide-induced pemphigus foliaceus. | 2001 Sep |
|
Blood pressure and stroke; the PROGRESS trial. | 2001 Sep |
|
[Changes of distensibility of the aorta in elderly patients during long-term therapy with various classes of hypotensive drugs (magnetic resonance tomography data)]. | 2002 |
|
[Tolerability and efficacy of retard form of indapamide in the treatment of hypertension in elderly patients (results of multicenter open non-comparative trial in Russian program ARGUS)]. | 2002 |
|
[Clinical assessment of efficacy and safety of noliprel in patients with hypertension]. | 2002 |
|
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. | 2002 |
|
Cutaneous drug reaction case reports: from the world literature. | 2002 |
|
[Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study]. | 2002 Aug |
|
[Arterial hypertension and tachycardia: monitoring the patient's personal drug therapy]. | 2002 Aug |
|
Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. | 2002 Aug |
|
[Indapamide-induced pemphigus foliaceus a sulfurous affair?]. | 2002 Aug-Sep |
|
Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study. | 2002 Dec |
|
Hypokalaemia and hyponatraemia due to indapamide. | 2002 Dec |
|
Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. | 2002 Dec |
|
Efficacious response with low-dose indapamide therapy in the treatment of type II diabetic patients with normal renal function or moderate renal insufficiency and moderate hypertension. | 2002 Jan-Feb |
|
Comparison of indapamide and low-dose hydrochlorothiazide monotherapy in black patients with mild to moderate hypertension. | 2002 Jul |
|
[Pigmented lesions secondary to indapamide]. | 2002 Jul |
|
Hyponatraemia and hypokalaemia caused by indapamide. | 2002 Jul 1 |
|
Hyponatraemia and hypokalaemia due to indapamide. | 2002 Mar 4 |
|
Stroke prevention: management of modifiable vascular risk factors. | 2002 May |
|
[PROGRESS--a trial on blood pressure lowering after stroke and TIA. ACE inhibitors and diuretics reduce the risk of new stroke]. | 2002 May 16 |
|
Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild to moderate essential hypertension. | 2002 May-Jun |
|
[Reflexion of French experts on the key points of the symposium]. | 2002 Oct |
|
[Treatment of hypertensive type 2 diabetes patients with microalbuminuria]. | 2002 Oct |
|
Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. | 2002 Oct |
|
Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. | 2002 Oct 4 |
|
[Hypertension and microcirculation]. | 2002 Sep |
|
[Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study]. | 2002 Sep |
|
Indapamide induced syncope in a patient with long QT syndrome. | 2002 Sep |
|
Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. | 2002 Sep |
|
Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms. | 2002 Sep 5 |
|
[Coversyl again]. | 2002 Sep 9 |
|
Progress and stroke--it's time to translate evidence into action. | 2002 Sep-Oct |
|
The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. | 2003 |
|
Drug-drug interactions among elderly patients hospitalized for drug toxicity. | 2003 Apr 2 |
|
Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. | 2003 Feb |
|
Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. | 2003 Feb |
|
Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. | 2003 Jan |
|
Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction? | 2003 Jan |
|
Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. | 2003 Jan |
|
[Secondary prevention after ischemic stroke]. | 2003 Jan 29 |
|
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. | 2003 Mar |
|
Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. | 2003 Mar |
|
Mechanisms of adrenergic control of sino-atrial node discharge. | 2003 Mar-Apr |
|
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. | 2003 May |
|
Optimization of a solid-phase extraction method for determination of indapamide in biological fluids using high-performance liquid chromatography. | 2003 May 5 |
Patents
Sample Use Guides
Usual Adult Dose for Edema Initial dose: 2.5 mg orally once a day. Usual Adult Dose for Hypertension Initial dose: 1.25 mg orally once a day.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49185
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
NDF-RT |
N0000175420
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
WHO-VATC |
QC03BA11
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
WHO-ATC |
C03BA11
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
NDF-RT |
N0000175359
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
LIVERTOX |
503
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
WHO-ATC |
C09BX01
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
WHO-ATC |
C10BX13
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
||
|
WHO-VATC |
QC09BX01
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
248-012-7
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
26807-65-8
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
INDAPAMIDE
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
M6245
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | Merck Index | ||
|
D007190
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
7203
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
3702
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
26807-65-8
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
CHEMBL406
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
SUB08169MIG
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
C29119
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
26807-65-8
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
3333
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | |||
|
5764
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY | RxNorm | ||
|
DB00808
Created by
admin on Tue Oct 22 00:33:48 UTC 2019 , Edited by admin on Tue Oct 22 00:33:48 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)